Myrexis, Inc. (Nasdaq: MYRX) announces the presentation of key preclinical findings of the Company's novel oral anti-interferon (OAI), MPI-0485520, at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE